InflaRx (IFRX) Interest & Investment Income (2017 - 2026)
InflaRx's (IFRX) quarterly Interest & Investment Income came in at $391928.2 in Q1 2026, down 24.54% year-on-year from $519382.7 in Q1 2025, and down 100.0% quarter-over-quarter from $2148.2 billion in Q4 2025.
InflaRx (IFRX) Interest & Investment Income (2017 - 2026) Analysis & Trends
InflaRx has disclosed Interest & Investment Income across 10 years of filings, most recently posting $391928.2 for Q1 2026.
- Interest & Investment Income for Q1 2026 came in at $391928.2, down 24.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $391928.2 (down 24.54% YoY), and the FY2025 annual result was $2.1 million, down 37.12% from the prior year.
- Interest & Investment Income came in at $391928.2 for Q1 2026 at InflaRx, down from $2148.2 billion in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $2148.2 billion in Q4 2025 to a low of $31382.8 in Q1 2022.
- The 5-year median for Interest & Investment Income is $1.7 million (2025), against an average of $202.8 billion.
- Across the five-year window, Interest & Investment Income surged 1559715401.69% in 2023 and sank 100.0% in 2024, its largest moves.
- InflaRx's Interest & Investment Income stood at $201.4 billion in 2022, then slumped by 100.0% to $3.0 million in 2023, then decreased by 6.88% to $2.8 million in 2024, then jumped by 77544274.8% to $2148.2 billion in 2025, then sank by 100.0% to $391928.2 in 2026.
- The last three Interest & Investment Income figures came in at $391928.2 (Q1 2026), $2148.2 billion (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 597,319.59 |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -14.79 Mn |
| 10 | InflaRx | 764.68 Mn | 764.68 Mn | 10,877.40 | 391,928.18 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 391,928.18 |
| Dec 31, 2025 | 2,148.16 Bn |
| Sep 30, 2025 | 1.70 Mn |
| Jun 30, 2025 | 1.15 Mn |
| Mar 31, 2025 | 519,382.67 |
| Sep 30, 2024 | 2.77 Mn |
| Jun 30, 2024 | 1.89 Mn |
| Mar 31, 2024 | 986,879.27 |
| Sep 30, 2023 | 2.97 Mn |
| Jun 30, 2023 | 1.68 Mn |
| Mar 31, 2023 | 489.48 Bn |
| Sep 30, 2022 | 201.41 Bn |
| Jun 30, 2022 | 117,762.51 |
| Mar 31, 2022 | 31,382.81 |
| Dec 31, 2021 | 125.14 Bn |
| Sep 30, 2021 | 101,376.26 |
| Jun 30, 2021 | 70,551.04 |
| Mar 31, 2021 | 27,697.59 |
| Dec 31, 2020 | 1,058.40 Bn |
| Sep 30, 2020 | 986,840.71 |